Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment from Its Phase Ib Study of PROHEMA(R)|
Fate Therapeutics, Inc. announced the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase Ib clinical trial of PROHEMA® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell transplantation for hematologic malignancy (the ProHema-01 trial). [Fate Therapeutics, Inc.]
Pluristem Receives Key 3D Cell Expansion Patent in Australia
Pluristem Therapeutics, Inc. announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose stromal cells, Pluristem’s key technology platform. [Pluristem Therapeutics, Inc.]
New Center in Nottingham to Collect Life-Saving Umbilical Cord Blood
Anthony Nolan opened two new cord blood collection centers in Queen’s Medical Centre and Nottingham City Hospital, thanks to funding from the Government’s Regional Growth Fund. [Anthony Nolan]
GE Capital Provides Credit Facility to SynGen, Inc.
GE Capital, Healthcare Financial Services announced that it has recently provided a $2.5 million senior secured credit facility to SynGen, Inc., a medical device company with a 510(k) approved bench-top system for isolating stem cells from umbilical cord blood, peripheral blood and bone marrow. [GE Capital, Healthcare Financial Services]
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.